The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Venetoclax and ibrutinib based approaches in CLL
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores venetoclax and ibrutinib based approaches in chronic lymphocytic leukemia (CLL). Specifically discussed is fixed-duration therapy with targeted agents as well as maintaining disease control using BTK inhibitors such as ibrutinib which, in contrast with venetoclax, which can provide deep remissions in some CLL patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
